The co-occurrence of JAK2 V617 F mutations and the BCR::ABL1 translocation in the same patient is rare and the current standard treatment for aggressive CML-myeloid BP with JAK2 V617 F mutations, particularly in patients who are not eligible for SCT, remains inadequate. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.